Skip to main content
Genscript Biotech Corporation logo

Genscript Biotech Corporation — Investor Relations & Filings

Ticker · 1548 ISIN · KYG3825B1059 LEI · 529900YIYUOJOXSAE372 HKEX Manufacturing
Open in API
Filings indexed 819 across all filing types
Latest filing 2024-12-10 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1548

About Genscript Biotech Corporation

http://www.genscript.com/investor-relat…

Genscript Biotech Corporation is a world-leading technology and service provider specializing in life science research and manufacturing. The company offers a comprehensive portfolio of services and products essential for fundamental life science research, translational biomedical research, and early drug discovery and development. Core offerings include custom synthesis of genes, peptides, proteins, and antibodies, alongside molecular cloning and oligonucleotide production. GenScript also provides Contract Development and Manufacturing Organization (CDMO) solutions for innovative therapies through its specialized subsidiaries. The corporation leverages biotechnology and AI-driven approaches to advance life science solutions.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT: LEGEND BIOTCH ANNOUNCES PRESENTATIONS AT THE 2024 ASH ANNUAL MEETING
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement filed by Genscript Biotech to the Hong Kong Exchange concerning clinical trial results and a presentation at a scientific conference (the 2024 ASH Annual Meeting). It does not report financial results (earnings release), changes in management or board, dividends, share transactions, M&A activity, proxy materials, or any other specific category. It simply informs the market of a corporate development (a conference presentation and trial data) and is not a formal reporting document such as an annual/interim report, ESG report, or investor presentation. Therefore, it falls into the general regulatory announcement fallback category: Regulatory Filings (RNS).
2024-12-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
Regulatory Filings Classification · 1% confidence The document is an FF301 Monthly Return filed with the Hong Kong Exchange detailing movements in authorized share capital, issued shares, share option exercises and other share capital changes for the month. It is neither an annual or interim financial report, earnings release, management discussion, nor a proxy or AGM material. It is a routine regulatory compliance filing reporting capital movements under the Exchange’s Listing Rules. This most closely aligns with the “Regulatory Filings” fallback category.
2024-12-03 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 1% confidence The document is a Hong Kong Stock Exchange Next Day Disclosure Return (Form FF305) detailing an issuance of new ordinary shares pursuant to a restricted share award scheme. It discloses a change in issued share capital (672,560 new shares), referencing Listing Rules 13.25A/17.27A. This is not an earnings release or regulatory announcement but a direct announcement of a share capital change. Therefore, it fits the 'Share Issue/Capital Change' category (Code: SHA).
2024-12-02 English
RESIGNATION OF ROTATING CHIEF EXECUTIVE OFFICER
Board/Management Information Classification · 1% confidence The document is an official announcement from GenScript Biotech Corporation regarding the resignation of its rotating Chief Executive Officer and related board and committee position changes, as well as appointment of a new chairman for a subsidiary’s board. This clearly pertains to senior management and board-level changes. Therefore, it fits the “Board/Management Information” category (MANG).
2024-12-02 English
Next Day Disclosure Return
Regulatory Filings
2024-11-21 English
Next Day Disclosure Return
Regulatory Filings
2024-11-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.